Io Biotech Inc (IOBT) Stock Price, Quote & News

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 29 80

Website: www.iobiotech.com

Address:

Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark

GTMStox Feb. 25 at 12:43 AM

$IOBT This would provide the cash infusion they need..

0 · Reply

GTMStox Feb. 24 at 11:00 PM

$IOBT Not sure if news is coming out of this...https://www.linkedin.com/posts/jeffbockmancellohealth_have-cancer-vaccines-come-of-age-or-do-they-activity-7418427751629754368-TWZe

1 · Reply

Nvidioso Feb. 24 at 9:35 PM

$IOBT news are coming!!

0 · Reply

GTMStox Feb. 24 at 3:53 PM

$IOBT Trimmed enough to where if this goes to 0...I'm all good. Treating it like an option play at this point.

0 · Reply

LordWorld Feb. 24 at 3:07 PM

$IOBT No need to be nervous 🤣 Life is beautiful, especially when you have money, a lot of money.

0 · Reply

LordWorld Feb. 24 at 3:05 PM

$IOBT I decided to sell all my shares completely.

1 · Reply

therealcryptocowboy Feb. 24 at 2:19 PM

$IOBT quit spreading false hope and lies!!!

1 · Reply

LordWorld Feb. 24 at 1:48 PM

$IOBT Remember these girls 🤣

0 · Reply

SilentJoker34 Feb. 24 at 12:10 PM

$IOBT 💎🧐🤙

0 · Reply

Fossick Feb. 24 at 2:48 AM

$IOBT Tell me you learned something from this.

1 · Reply

IO Biotech Provides Corporate Update

Jan 21, 2026, 5:30 AM EST - 4 weeks ago

IO Biotech Announces Exploration of Strategic Alternatives

Dec 15, 2025, 4:05 PM EST - 2 months ago

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

Nov 26, 2025, 10:46 AM EST - 3 months ago

IO Biotech Announces Participation in Upcoming December Investor Conferences

Nov 14, 2025, 8:05 AM EST - 3 months ago

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 12, 2025, 8:30 AM EST - 3 months ago

IO Biotech Announces Participation in Upcoming Investor Conferences

Nov 7, 2025, 9:00 AM EST - 3 months ago

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 20, 2025, 2:30 AM EDT - 4 months ago

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Sep 29, 2025, 7:05 AM EDT - 5 months ago

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Sep 23, 2025, 8:05 AM EDT - 5 months ago

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Sep 9, 2025, 11:41 AM EDT - 6 months ago

IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 14, 2025, 4:05 PM EDT - 6 months ago

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 12, 2025, 4:17 PM EDT - 7 months ago

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma

Aug 11, 2025, 8:24 AM EDT - 7 months ago

IO Biotech's cancer vaccine shows improvement in late-stage study goal

Aug 11, 2025, 8:00 AM EDT - 7 months ago

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Aug 10, 2025, 8:00 AM EDT - 7 months ago

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

May 20, 2025, 8:05 AM EDT - 10 months ago

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 14, 2025, 8:05 AM EDT - 10 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Apr 26, 2025, 3:05 PM EDT - 10 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 10 months ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

Mar 25, 2025, 4:35 PM EDT - 1 year ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 18, 2025, 8:00 AM EDT - 1 year ago

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Mar 4, 2025, 4:17 PM EST - 1 year ago

IO Biotech Reports 2024 Business Highlights

Feb 23, 2025, 12:07 PM EST - 1 year ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Feb 20, 2025, 8:05 AM EST - 1 year ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Feb 4, 2025, 8:05 AM EST - 1 year ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Jan 9, 2025, 8:05 AM EST - 1 year ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Dec 20, 2024, 8:05 AM EST - 1 year ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Nov 12, 2024, 7:05 AM EST - 1 year ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 7, 2024, 10:00 AM EST - 1 year ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Oct 4, 2024, 9:00 AM EDT - 1 year ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 14, 2024, 2:30 AM EDT - 1 year ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Aug 30, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 13, 2024, 7:05 AM EDT - 1 year ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

May 23, 2024, 8:30 AM EDT - 1 year ago

IO Biotech to Present at Jefferies Global Healthcare Conference

May 14, 2024, 7:55 AM EDT - 1 year ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 24, 2024, 4:30 PM EDT - 1 year ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 2 years ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 9, 2024, 12:00 PM EDT - 2 years ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 5, 2024, 8:30 AM EDT - 2 years ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Mar 6, 2024, 4:11 PM EST - 2 years ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:40 PM EST - 2 years ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Jan 3, 2024, 3:04 AM EST - 2 years ago

IO Biotech: A Phase 3 Company Getting No Respect

Dec 21, 2023, 8:30 AM EST - 2 years ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Nov 13, 2023, 8:12 AM EST - 2 years ago

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:00 AM EST - 2 years ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 10, 2023, 8:00 AM EST - 2 years ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 1, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

GTMStox Feb. 25 at 12:43 AM

$IOBT This would provide the cash infusion they need..

0 · Reply

GTMStox Feb. 24 at 11:00 PM

$IOBT Not sure if news is coming out of this...https://www.linkedin.com/posts/jeffbockmancellohealth_have-cancer-vaccines-come-of-age-or-do-they-activity-7418427751629754368-TWZe

1 · Reply

Nvidioso Feb. 24 at 9:35 PM

$IOBT news are coming!!

0 · Reply

GTMStox Feb. 24 at 3:53 PM

$IOBT Trimmed enough to where if this goes to 0...I'm all good. Treating it like an option play at this point.

0 · Reply

LordWorld Feb. 24 at 3:07 PM

$IOBT No need to be nervous 🤣 Life is beautiful, especially when you have money, a lot of money.

0 · Reply

LordWorld Feb. 24 at 3:05 PM

$IOBT I decided to sell all my shares completely.

1 · Reply

therealcryptocowboy Feb. 24 at 2:19 PM

$IOBT quit spreading false hope and lies!!!

1 · Reply

LordWorld Feb. 24 at 1:48 PM

$IOBT Remember these girls 🤣

0 · Reply

SilentJoker34 Feb. 24 at 12:10 PM

$IOBT 💎🧐🤙

0 · Reply

Fossick Feb. 24 at 2:48 AM

$IOBT Tell me you learned something from this.

1 · Reply

therealcryptocowboy Feb. 24 at 2:24 AM

$IOBT

1 · Reply

LordWorld Feb. 23 at 5:36 PM

$IOBT Tomorrow, February 24-26, 2026, the Global Life Science Partnering & Investor Conference 2026, organized by Biocom California, begins in La Jolla (a suburb of San Diego, California). This conference is considered one of the most prestigious dealmaking events of the year in the biotech sector. Key Event Details: Format: This is not a scientific convention, but a platform for investment negotiations and partnerships. Attendees: Over 500 investors and senior executives (CEOs, heads of business development) from 20 countries. Confirmed giants seeking acquisitions include AbbVie, Amgen, Eli Lilly, and Pfizer. Main Activity: Over 1,000 closed one-on-one meetings to discuss licensing, financing, and strategic collaborations (M&A).https://www.biocom.org/conferences/global-partnering-conference/

3 · Reply

LordWorld Feb. 22 at 6:01 PM

$IOBT Torben Elmertoft: Vikar Social & sundhedsområdet "Exciting that you will be exploring strategic alternatives. Several observers have previously highlighted that the company was working with an interesting product concept, so it's encouraging to see that this value is being actively assessed. It will be interesting to follow which options come into play and how they align with the long-term potential of the pipeline.

0 · Reply

LordWorld Feb. 21 at 9:59 AM

$IOBT 🤣🤣🤣👍👍👍This is always the case 100% of the time.

0 · Reply

GTMStox Feb. 21 at 1:11 AM

$IOBT and this will happen as it happens to me all the time

1 · Reply

GTMStox Feb. 21 at 1:09 AM

$IOBT overall trashy week. Let’s call it what it is. This is a big gamble. You’re definitely not a bull based off a fundamentals as at this point it is pure speculation. Bulls are hoping that they recent 13 G filings with Point 72 and Chernett means something. We’re also banking on the fact that there have seen other biotech penny stock turnarounds in the same situation. Once again, all is based off of speculation and hope. It actually makes a lot more sense to take the bearish stance on this but one thing I’ve realized in all my years of trading is that the market doesn’t make sense…so keep hope alive!

1 · Reply

therealcryptocowboy Feb. 21 at 1:08 AM

$IOBT I’ll hold 1 more week. If nothing I’m done. Sick of losing money everyday😂

1 · Reply

therealcryptocowboy Feb. 20 at 9:28 PM

$IOBT we really knocked it out of the park today!!!

0 · Reply

LordWorld Feb. 20 at 7:13 PM

$IOBT It feels like IOBT is lying on the resuscitation table and has fallen into a coma.🚑🚨🤣.

0 · Reply

LordWorld Feb. 20 at 6:38 PM

$IOBT They have a report in early March. Everyone is waiting for the data. Overall Survival data. But the preliminary data is already in IOBT's hands. And most likely, all interested parties in Big Tech are aware of this data.

0 · Reply

Superman71 Feb. 20 at 6:03 PM

$IOBT Steven Cohen bought over 4 million shares on the 6th at .40. His hedge fund now owns over 5%. This definitely goes to $3. Follow the money chumps!

0 · Reply

LordWorld Feb. 20 at 2:07 PM

$IOBT All the latest announcements were released on Friday. January 30th Raymond James, February 6th Point 72 -5.6%, February 13th Chernett Jorey -6.3%. And all were released after the close of the main session. Today is February 20th, Friday.

0 · Reply

Market Cap	24.31M
Revenue (ttm)	0.00
Net Income (ttm)	-95.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	18.31

Volume	289,100
Avg Vol	11,780,784
Day's Range	N/A - N/A
Shares Out	71.95M
Stochastic %K	20%
Beta	0.47
Analysts	Sell
Price Target	$1.62